Iberdomide and mezigdomide, which are novel CRBN E3 ligase modulators (CELMoDs), showed higher efficacy in lenalidomide-resistance MM patients in ongoing clinical trials. This evidence concerns the gene CRBN and Miyoshi myopathy.